| Dr Mekhala Stephen, MD | |
|
163 Libbey Pkwy, Suite 301, Weymouth, MA 02189-3101 | |
| (781) 337-4224 | |
| (781) 335-0429 |
| Full Name | Dr Mekhala Stephen |
|---|---|
| Gender | Female |
| Speciality | Anesthesiology |
| Experience | 37 Years |
| Location | 163 Libbey Pkwy, Weymouth, Massachusetts |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023072287 | NPI | - | NPPES |
| AA42871 | Other | MA | HARVARD PILGRIM |
| J27684 | Other | MA | BLUE SHIELD |
| 98014 | Other | MA | FALLON |
| 469489 | Other | MA | TUFTS HEALTH PLAN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 213974 (Massachusetts) | Primary |
| 207LP2900X | Anesthesiology - Pain Medicine | 213974 (Massachusetts) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| South Shore Hospital | South weymouth, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Coastal Medical Associates | 7113029257 | 412 |
News Archive
Scancell Holdings Plc, the developer of therapeutic cancer vaccines, announces that a treatment utilising a DNA vaccine based on its ImmunoBody® technology, in combination with ImmuneRegen BioSciences, Inc.®'s lead compound, Homspera®, has significantly improved the immune response of the vaccine in an animal model. Follow-up studies are currently being performed to optimize the effects of Homspera in enhancing the next generation of Scancell's cancer vaccines.
A new national initiative involving UT Southwestern Medical Center will match volunteers who want to take part in medical research studies with the scientists who are leading those studies.
More people die of lung cancer each year than breast, colon, and prostate cancers combined. One particularly lethal form of the disease is lung adenocarcinoma or LUAD, which afflicts both smokers and non-smokers.
A team of international scientists has recently demonstrated the usefulness of cetylpyridinium chloride-containing mouthwashes in inhibiting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and reducing the risk of viral transmission. The study is currently available on the bioRxiv* preprint server.
First Consulting Group, Inc. has announced that it has expanded its long-standing relationship with AstraZeneca. FCG will help AstraZeneca deliver a new off-the-shelf document management solution and upgrade its manufacturing site document management system to FirstDoc™.
› Verified 2 days ago
| Entity Name | South Suburban Gastroenterology Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114948478 PECOS PAC ID: 9931194412 Enrollment ID: O20040415000288 |
News Archive
Scancell Holdings Plc, the developer of therapeutic cancer vaccines, announces that a treatment utilising a DNA vaccine based on its ImmunoBody® technology, in combination with ImmuneRegen BioSciences, Inc.®'s lead compound, Homspera®, has significantly improved the immune response of the vaccine in an animal model. Follow-up studies are currently being performed to optimize the effects of Homspera in enhancing the next generation of Scancell's cancer vaccines.
A new national initiative involving UT Southwestern Medical Center will match volunteers who want to take part in medical research studies with the scientists who are leading those studies.
More people die of lung cancer each year than breast, colon, and prostate cancers combined. One particularly lethal form of the disease is lung adenocarcinoma or LUAD, which afflicts both smokers and non-smokers.
A team of international scientists has recently demonstrated the usefulness of cetylpyridinium chloride-containing mouthwashes in inhibiting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and reducing the risk of viral transmission. The study is currently available on the bioRxiv* preprint server.
First Consulting Group, Inc. has announced that it has expanded its long-standing relationship with AstraZeneca. FCG will help AstraZeneca deliver a new off-the-shelf document management solution and upgrade its manufacturing site document management system to FirstDoc™.
› Verified 2 days ago
| Entity Name | Coastal Medical Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932175684 PECOS PAC ID: 7113029257 Enrollment ID: O20070221000057 |
News Archive
Scancell Holdings Plc, the developer of therapeutic cancer vaccines, announces that a treatment utilising a DNA vaccine based on its ImmunoBody® technology, in combination with ImmuneRegen BioSciences, Inc.®'s lead compound, Homspera®, has significantly improved the immune response of the vaccine in an animal model. Follow-up studies are currently being performed to optimize the effects of Homspera in enhancing the next generation of Scancell's cancer vaccines.
A new national initiative involving UT Southwestern Medical Center will match volunteers who want to take part in medical research studies with the scientists who are leading those studies.
More people die of lung cancer each year than breast, colon, and prostate cancers combined. One particularly lethal form of the disease is lung adenocarcinoma or LUAD, which afflicts both smokers and non-smokers.
A team of international scientists has recently demonstrated the usefulness of cetylpyridinium chloride-containing mouthwashes in inhibiting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and reducing the risk of viral transmission. The study is currently available on the bioRxiv* preprint server.
First Consulting Group, Inc. has announced that it has expanded its long-standing relationship with AstraZeneca. FCG will help AstraZeneca deliver a new off-the-shelf document management solution and upgrade its manufacturing site document management system to FirstDoc™.
› Verified 2 days ago
| Entity Name | South Shore Anesthesia Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770530388 PECOS PAC ID: 4688571417 Enrollment ID: O20080424000079 |
News Archive
Scancell Holdings Plc, the developer of therapeutic cancer vaccines, announces that a treatment utilising a DNA vaccine based on its ImmunoBody® technology, in combination with ImmuneRegen BioSciences, Inc.®'s lead compound, Homspera®, has significantly improved the immune response of the vaccine in an animal model. Follow-up studies are currently being performed to optimize the effects of Homspera in enhancing the next generation of Scancell's cancer vaccines.
A new national initiative involving UT Southwestern Medical Center will match volunteers who want to take part in medical research studies with the scientists who are leading those studies.
More people die of lung cancer each year than breast, colon, and prostate cancers combined. One particularly lethal form of the disease is lung adenocarcinoma or LUAD, which afflicts both smokers and non-smokers.
A team of international scientists has recently demonstrated the usefulness of cetylpyridinium chloride-containing mouthwashes in inhibiting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and reducing the risk of viral transmission. The study is currently available on the bioRxiv* preprint server.
First Consulting Group, Inc. has announced that it has expanded its long-standing relationship with AstraZeneca. FCG will help AstraZeneca deliver a new off-the-shelf document management solution and upgrade its manufacturing site document management system to FirstDoc™.
› Verified 2 days ago
| Entity Name | South Shore Hospital Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134227606 PECOS PAC ID: 4385546217 Enrollment ID: O20090818000015 |
News Archive
Scancell Holdings Plc, the developer of therapeutic cancer vaccines, announces that a treatment utilising a DNA vaccine based on its ImmunoBody® technology, in combination with ImmuneRegen BioSciences, Inc.®'s lead compound, Homspera®, has significantly improved the immune response of the vaccine in an animal model. Follow-up studies are currently being performed to optimize the effects of Homspera in enhancing the next generation of Scancell's cancer vaccines.
A new national initiative involving UT Southwestern Medical Center will match volunteers who want to take part in medical research studies with the scientists who are leading those studies.
More people die of lung cancer each year than breast, colon, and prostate cancers combined. One particularly lethal form of the disease is lung adenocarcinoma or LUAD, which afflicts both smokers and non-smokers.
A team of international scientists has recently demonstrated the usefulness of cetylpyridinium chloride-containing mouthwashes in inhibiting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and reducing the risk of viral transmission. The study is currently available on the bioRxiv* preprint server.
First Consulting Group, Inc. has announced that it has expanded its long-standing relationship with AstraZeneca. FCG will help AstraZeneca deliver a new off-the-shelf document management solution and upgrade its manufacturing site document management system to FirstDoc™.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mekhala Stephen, MD 163 Libbey Pkwy, Suite 301, Weymouth, MA 02189-3101 Ph: (781) 337-4224 | Dr Mekhala Stephen, MD 163 Libbey Pkwy, Suite 301, Weymouth, MA 02189-3101 Ph: (781) 337-4224 |
News Archive
Scancell Holdings Plc, the developer of therapeutic cancer vaccines, announces that a treatment utilising a DNA vaccine based on its ImmunoBody® technology, in combination with ImmuneRegen BioSciences, Inc.®'s lead compound, Homspera®, has significantly improved the immune response of the vaccine in an animal model. Follow-up studies are currently being performed to optimize the effects of Homspera in enhancing the next generation of Scancell's cancer vaccines.
A new national initiative involving UT Southwestern Medical Center will match volunteers who want to take part in medical research studies with the scientists who are leading those studies.
More people die of lung cancer each year than breast, colon, and prostate cancers combined. One particularly lethal form of the disease is lung adenocarcinoma or LUAD, which afflicts both smokers and non-smokers.
A team of international scientists has recently demonstrated the usefulness of cetylpyridinium chloride-containing mouthwashes in inhibiting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and reducing the risk of viral transmission. The study is currently available on the bioRxiv* preprint server.
First Consulting Group, Inc. has announced that it has expanded its long-standing relationship with AstraZeneca. FCG will help AstraZeneca deliver a new off-the-shelf document management solution and upgrade its manufacturing site document management system to FirstDoc™.
› Verified 2 days ago
Ari Lev Moskowitz, MD Anesthesiology Medicare: May Accept Medicare Assignments Practice Location: 55 Fogg Road, Weymouth, MA 02190 Phone: 781-624-8000 Fax: 781-878-6750 | |
David F Demick, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 163 Libbey Industrial Pkwy, Suite 301, Weymouth, MA 02189 Phone: 781-337-4224 Fax: 781-335-0429 | |
James E Hughes, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 163 Libbey Pkwy, Suite 301, Weymouth, MA 02189 Phone: 781-337-4224 Fax: 781-335-0429 | |
Dr. Timothy Frederick Ayers, D.O. Anesthesiology Medicare: May Accept Medicare Assignments Practice Location: 163 Libbey Pkwy, Suite 301, Weymouth, MA 02189 Phone: 781-337-4224 Fax: 781-335-0429 | |
Dr. Mark E Wechsler, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 163 Libbey Pkwy, Suite 301, Weymouth, MA 02189 Phone: 781-337-4224 Fax: 781-335-0429 | |
Carol H Selland, CRNA Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 696 Main St, Weymouth, MA 02190 Phone: 781-331-3820 Fax: 781-331-1076 |